| __timestamp | Intra-Cellular Therapies, Inc. | MannKind Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 21226345 | 100244000 |
| Thursday, January 1, 2015 | 87718074 | 29674000 |
| Friday, January 1, 2016 | 93831530 | 14917000 |
| Sunday, January 1, 2017 | 79419009 | 14118000 |
| Monday, January 1, 2018 | 132166913 | 8737000 |
| Tuesday, January 1, 2019 | 89124838 | 6900000 |
| Wednesday, January 1, 2020 | 65782137 | 6248000 |
| Friday, January 1, 2021 | 88845513 | 12312000 |
| Saturday, January 1, 2022 | 134715000 | 19721000 |
| Sunday, January 1, 2023 | 180142000 | 31283000 |
Unleashing insights
In the competitive world of biotechnology, strategic investment in research and development (R&D) is crucial for innovation and growth. Over the past decade, Intra-Cellular Therapies, Inc. and MannKind Corporation have demonstrated contrasting approaches to R&D spending.
From 2014 to 2023, Intra-Cellular Therapies, Inc. increased its R&D expenses by over 750%, peaking in 2023 with a remarkable $180 million investment. This aggressive strategy underscores their commitment to pioneering new treatments and maintaining a competitive edge. In contrast, MannKind Corporation's R&D spending saw a significant decline, dropping by nearly 70% from its 2014 levels. This shift may reflect a strategic pivot or resource reallocation.
These divergent paths highlight the varied strategies within the biotech sector, where R&D investment can be a key differentiator in achieving long-term success.
R&D Insights: How Novartis AG and MannKind Corporation Allocate Funds
Research and Development: Comparing Key Metrics for Pfizer Inc. and MannKind Corporation
Sanofi or Intra-Cellular Therapies, Inc.: Who Invests More in Innovation?
Teva Pharmaceutical Industries Limited vs MannKind Corporation: Strategic Focus on R&D Spending
Research and Development Investment: Incyte Corporation vs Intra-Cellular Therapies, Inc.
R&D Insights: How Intra-Cellular Therapies, Inc. and Alpine Immune Sciences, Inc. Allocate Funds
Comparing Innovation Spending: Summit Therapeutics Inc. and MannKind Corporation
Who Prioritizes Innovation? R&D Spending Compared for Sarepta Therapeutics, Inc. and MannKind Corporation
R&D Insights: How Verona Pharma plc and MannKind Corporation Allocate Funds
R&D Spending Showdown: Perrigo Company plc vs MannKind Corporation
Research and Development Investment: Vericel Corporation vs MannKind Corporation
R&D Insights: How MannKind Corporation and Taro Pharmaceutical Industries Ltd. Allocate Funds